A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
about
A kinase-independent role for EGF receptor in autophagy initiationChloroquine and hydroxychloroquine for cancer therapyYou eat what you are: autophagy inhibition as a therapeutic strategy in leukemiaNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerThymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cellsChloroquine is a zinc ionophoreAddition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohortA phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsEGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.Molecular pathways: autophagy in cancer--a matter of timing and context.Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.The apoptotic effect of 1'S-1'-Acetoxychavicol Acetate (ACA) enhanced by inhibition of non-canonical autophagy in human non-small cell lung cancer cells.Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment.Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.EGFR inhibitors and autophagy in cancer treatment.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.Hydroxychloroquine retinopathy.Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors.Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.Targeting autophagy in cancer.The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.Hypoxia-inducible factor-1α promotes endometrial stromal cells migration and invasion by upregulating autophagy in endometriosis.Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis.Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases.Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies.Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulationHydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophagesHydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study
P2860
Q24314943-FC494571-9499-4EC7-9382-BC8EF1C4D110Q26827797-76881C36-1772-4055-AFA8-DF283569EE98Q26998971-C4B2B2C8-1299-4A4B-9848-9A2AAC8F1803Q28259999-B47B36AD-FDA5-4628-86C0-39348BDA9DC9Q28536969-B2CD6780-FDB2-4957-8FAA-D707EFABB910Q28543470-0695E2C1-6419-46AA-A9EA-4774B6181DFFQ33422577-F138919E-D11A-47FA-AEAF-E555B8EF6905Q34483485-8C047785-595E-4F5E-8E13-8636113E11F3Q34782417-96781C87-806E-4C7C-BE68-852A34D4C7DDQ35044465-28BC4EF2-ED46-45D1-869C-722E13ACA1FAQ35086734-CA425B48-A199-416F-9950-F07229D32C42Q35846545-FA770B6A-C274-4947-ABF5-4EA84F6D86D3Q36270008-DB524CB5-9BE5-492D-A154-8A5E408D319BQ36398719-47BFCF2E-6FA5-4E3C-A10F-6628CDE24080Q37256737-97E0E88A-34B9-4D28-9262-BDE4BBF22208Q37299613-F92AB94B-C517-4503-8357-8D657C2385E1Q37701461-3B01A682-6879-440A-9A5B-B44E1CF2C4DEQ37744911-626D7CFC-6A05-4305-B74E-2B57F2331E09Q38257898-42A05FF5-EECB-401F-8741-7470C5E77C82Q38258948-E2679904-31A0-4DDB-9689-41855CE55ADBQ38745430-A4C85198-7E27-43DB-9E3C-847849ADD60EQ38795278-7805480E-38A5-45C1-BD79-294792BBEEC8Q38929614-150FB9A0-2285-4171-B019-2058099F35CFQ39009616-4DED359A-BACD-4BFB-BE69-86D68542D375Q39172826-12CF089C-DF98-4F6B-85D3-A90DC0C42C48Q39378223-05A7C421-5847-4C2A-A9EB-B862804427A2Q40386800-7E0D316A-205D-4A52-BC83-4F9FC77E2C82Q41912265-EDDF744C-592F-4FB3-B970-2A27E822FA4BQ41926158-ECF1648F-6285-4619-BC79-4CF365385724Q42583016-C1B9551F-25A8-4D85-B5EF-3F63FC9C60A7Q45055760-5F784792-7BEE-49A7-B9CF-D46FD4893FDDQ45397879-B9E45DF9-E758-4395-AD65-D3E9E20E85EDQ46218671-95D772A8-DB8F-4C10-8197-6CD4004D52D5Q47138361-F9A6218C-3184-42B5-81D3-6A0B678E31FDQ47162451-5071C27C-972F-4A90-A63B-8BE44795D59BQ47328228-8EACA7F6-A317-416C-8726-E771AEE76A17Q55280808-3BD8131B-0D31-4921-A2E2-2A480B91E31FQ57246602-11127998-F795-4ECE-BDE1-6AF786AFF729Q58104261-7C49AEA5-FEB6-4BDC-A392-B54D39B65946Q58735775-08FF9674-DB34-4C53-B237-9A3CEE2197B9
P2860
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I study of erlotinib a ...... ced non-small-cell lung cancer
@en
A phase I study of erlotinib a ...... ed non-small-cell lung cancer.
@nl
type
label
A phase I study of erlotinib a ...... ced non-small-cell lung cancer
@en
A phase I study of erlotinib a ...... ed non-small-cell lung cancer.
@nl
prefLabel
A phase I study of erlotinib a ...... ced non-small-cell lung cancer
@en
A phase I study of erlotinib a ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P1476
A phase I study of erlotinib a ...... ced non-small-cell lung cancer
@en
P2093
Alice T Shaw
Alona Muzikansky
Jeffrey E Settleman
Jeffrey G Supko
Jennifer S Temel
Joel W Neal
Lecia V Sequist
Panos Fidias
Patricia O McCarthy
Rebecca S Heist
P2860
P304
P356
10.1097/JTO.0B013E318262DE4A
P577
2012-10-01T00:00:00Z